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Abstract: In patients with non-IgE-mediated milk allergy, a cellular mechanism of delayed-type
hypersensitivity (DTH) is considered. Recent findings prove that cell-mediated reactions can be
antigen-specifically inhibited by extracellular vesicles (EVs) carrying miRNA-150. We sought to
establish a new mouse model of DTH to casein and test the possibility of antigen-specific suppression
of the inflammatory reaction. To produce soluble antigenic peptides, casein was subjected to alkaline
hydrolysis. DTH reaction to casein was induced in CBA, C57BL/6, and BALB/c mice by intradermal
(id) injection of the antigen. Cells collected from spleens and lymph nodes were positively or
negatively selected and transferred to naive recipients intravenously (iv). CBA mice were tolerized by
iv injection of mouse erythrocytes conjugated with casein antigen and following id immunization with
the same antigen. Suppressive EVs were harvested from cell cultures and serum of tolerized donors
by means of ultrafiltration and ultracentrifugation for further therapeutic utilization. The newly
established mouse model of DTH to casein was mediated by CD4+ Th1 cells and macrophages,
while EVs produced by casein-tolerized animals effectively suppressed effector cell response, in an
miRNA-150-dependent manner. Altogether, our observations contribute to the current understanding
of non-IgE-mediated allergy to casein and of the possibilities to downregulate this reaction.
Keywords: cow’s milk allergy; casein; cell-mediated reactions; delayed-type hypersensitivity;
extracellular vesicles; miRNA-150
1. Introduction
Cow’s milk allergy is one of the most common food allergies in children. It is hard to precisely
estimate the prevalence of milk allergy, because its symptoms are often mistaken with lactose
intolerance, a non-immunological reaction [1]. Allergy to cow’s milk usually manifests itself as a type I
hypersensitivity reaction that is IgE-mediated and occurs immediately after contact with the allergen
in sensitized individuals. There is also a group of patients with onset delayed more than 20 h after the
exposure to the allergen and where the reaction does not depend on IgE level [2–4]. This suggests
involvement of another mechanism likely cell-mediated.
Delayed-type hypersensitivity (DTH) to common allergens is far more difficult to diagnose than
type I allergy and thus remains a challenge for clinicians. Symptoms of non-IgE-mediated allergy to
food proteins are mostly gastro-intestinal and include malabsorption, bloody diarrhea, emesis, pallor,
lethargy, and weight loss [1,5].
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DTH, classified by Gell and Coombs as a type IV allergic reaction, has been widely studied in
drug-induced models, and a new subclassification has been established according to the manifestation
of the allergy and the type of cells involved in the reaction. Subtype IVa is mediated by Th1 lymphocytes
and macrophages (manifested by bullous exanthem), while IVb by Th2 lymphocytes and eosinophils
is accompanied by maculopapular exanthem. Subtype IVc is mediated by cytotoxic T lymphocytes,
and either maculopapular or bullous exanthem can be observed as the clinical symptoms. Pustular
exanthem is a hallmark of the IVd subtype, to which reaction depends on T lymphocytes producing
IL-8 and GM-CSF that activate neutrophils [6]. However, it still remains an open question if DTH
subtypes underlie the non-IgE-mediated allergy to casein.
Cow’s milk consists of around 30 different proteins, from which caseins constitute approximately
80% [7]. Currently, the most effective treatment of non-IgE-dependent allergy to cow’s milk is the
elimination of the offending food and all products that may contain its proteins from child’s diet. If an
infant with a cow’s milk allergy is breastfed, then it should also be eliminated from the mother’s diet.
This method is a great burden for parents, since milk proteins, such as casein, can be found not only
in dairy products but also in many processed foods [1,8]. Total avoidance of specific food may even
predispose infants to develop an allergy by disturbing IgA-mediated oral tolerance [9,10].
Recently, it was proved that cell-mediated allergic reactions to haptens can be inhibited by
exosome-like extracellular vesicles (EVs) carrying miRNA-150 [11]. Exosomes representing a population
of small EVs have recently become the subject of increasing interest as a new means of intercellular
communication. They are produced intracellularly in multivesicular bodies and are released by
exocytosis. EVs can contain a “cargo” of miRNA that may be delivered to the acceptor cell and affect
its physiology [12]. In a murine model of contact sensitivity to haptens, EVs carrying miRNA-150
had the capacity to antigen-specifically target effector T cells and suppress the inflammation [11].
These EVs were produced by a distinct population of CD8+ suppressor T (Ts) lymphocytes, but not
from FoxP3+ regulatory T cells, after intravenous administration of syngeneic erythrocytes conjugated
with hapten to naive mice. Moreover, they became antigen-specific when coated with IgM light chains,
produced by B1 lymphocytes after contact immunization with the same hapten. The suppressive Ts
cell-derived miRNA-150-carrying EVs and B1 cell-produced antibody light chains were described to
act together as soluble T suppressor factor (TsF) [13]. Our preliminary data suggest that analogous
tolerance mechanism mediated by Ts cell EV-contained miRNA-150 could also be induced in DTH
to ovalbumin.
Our study aimed to describe the effector mechanisms and to standardize a new, mouse model
of DTH to casein antigen. For this purpose, we established a method of obtaining a soluble casein
(Cas) antigen that appears to be safe to use in an animal model of active immunization and to
induce cellular inflammatory response. The next aim of our research was to test the possibility of
antigen-specific inhibition of DTH reactions to protein antigen, such as Cas, in adoptive transfer and in
active immunization.
2. Materials and Methods
2.1. Mice
Mice of CBA, BALB/c, and C57BL/6 inbred strains were obtained from the breeding unit of the
Faculty of Medicine, Jagiellonian University Medical College in Krakow, Poland. Animals were fed
with casein-free chow supplied by Labofeed H (Kcynia, Poland). All experiments were conducted
according to the guidelines of the Animal Care and Use Committee of the Jagiellonian University
Medical College and Yale School of Medicine, New Haven, CT (Permit Number 07381) and under
ethical approval of the 1st Local Ethics Committee in Krakow (approval no. 243/2015). Control and
treatment groups consisted of 4–5 animals.
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2.2. Casein Alkaline Hydrolysis
Insoluble bovine casein (Sigma-Aldrich, St Louis, MO, USA), containing all casein fractions, i.e.,
α-s1, α-s2, β, and κ-casein, was suspended in NaHCO3 (0.5 M) in a 1:8 ratio (w/v) and hydrolyzed in
37 ◦C for 5–7 h with occasional mixing. The solution was then kept at room temperature for subsequent
48 h. Next, all probes were centrifuged (3300 g, 15 min), and the soluble fraction was dialyzed to DPBS.
The remaining pellet was resuspended in NaOH (1 M), adjusted to pH = 10 with HCl solution, mixed,
and kept at room temperature for the next 24 h. Again, the resulting soluble fraction was processed as
above. Apart from immunogenicity testing, soluble Cas fractions after hydrolysis with NaHCO3 or
NaOH were mixed and then dialyzed to either DPBS (for coupling with erythrocytes) or 0.9% NaCl
(for immunization). Yielded soluble Cas antigen was filtrated, and the protein concentration was then
assessed with a UV spectrophotometer at 280 nm.
2.3. Active Immunization
Mice under light anesthesia were immunized with the Cas antigen by intradermal administration
of a total of 200 µL of soluble Cas peptides (0.5 mg/ml) administered into 4 separate sides of the
abdomen on Days 0 and 1. On Day 5, mice were challenged on both ears by intradermal administration
of 10 µL of the same Cas solution. The increase in ear thickness was measured by a blinded observer
using an engineer’s micrometer (Mitutoyo, Kawasaki, Japan) from 24 to 120 h later [14]. Background
earlobe thickness was subtracted to obtain a value of ear thickness increase for each mouse, while
nonspecific increase in earlobe thickness in non-immunized, but challenged littermates was subtracted
from experimental groups to yield a net swelling value expressed as delta ± standard error (SE)
[U×10−2 mm].
2.4. Adoptive Transfer of DTH Effector Cells
Cas-immunized mice (see above) were sacrificed on Day 5 by means of cervical dislocation under
deep anesthesia. Effector cells were obtained from spleens and lymph nodes, and their single cell
suspensions in DPBS were transferred intravenously to naive recipients (7 × 107 cells per mouse).
The next day, animals were ear-challenged by intradermal administration of 10 µL of soluble Cas, and
subsequent earlobe thickness was measured as above [14].
2.5. Negative Selection Assay
DTH effector cell suspensions from spleens and lymph nodes of Cas-immunized mice were
incubated with monoclonal antibodies specific for CD4 (rat IgG2b antibody, GK1.5 clone) or CD8 (rat
IgG2b antibody, TIB-105 clone, both cell lines were cultured and produced monoclonal antibodies
were chromatographically purified at Department of Immunology, Jagiellonian University Medical
College, Krakow, Poland) markers. The rabbit complement (BIOMED, Lublin, Poland) was then added
and suspensions were incubated for 1 h in a 37 ◦C water-bath. DTH effector cells were depleted
of macrophages by triple filtration through a 70 µm nylon mesh. Selection was followed by Ficoll
centrifugation to remove dead cells. Selected viable cells were suspended in DPBS and administered
to naive mice intravenously in adoptive transfer (see above) [15].
2.6. Positive Selection Assay
Cell suspensions from spleens and lymph nodes of mice immunized or tolerized with Cas antigen
or Cas-coupled erythrocytes, respectively, were positively selected on MiniMACS MS columns with
microbeads coated with monoclonal antibodies anti-CD4 or anti-CD8 according to manufacturer’s
procedures (Miltenyi Biotec, Bergisch Gladbach, Germany). Selected viable cells were suspended in
DPBS and intravenously administered to naive mice in adoptive transfer (see above).
Nutrients 2019, 11, 907 4 of 18
2.7. Induction and Separation of Ts cell EVs from Cell Supernatants
Mice, on Days 0 and 4, were injected intravenously with 10% suspension of syngeneic erythrocytes
conjugated with Cas antigen in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)
for activation of coupling process. This induced a generation of miRNA-150-carrying EVs by Ts cells.
On Days 7 and 8, Cas antigen without an adjuvant was administered intradermally into 4 separate
sites of the abdomen (100 µg per mouse, see above) in order to induce production of specific IgM light
chains by B1 lymphocytes. Spleens and lymph nodes of tolerized mice were harvested on Day 10
and their single cell suspensions, containing Ts cells and B1 lymphocytes, were cultured for 48 h in
protein-free Mishell-Dutton medium (MDM, 2 × 107 cells per ml, 37 ◦C, 5% CO2). Supernatants from
cell cultures were then centrifuged twice (300× g and 3000× g, for 15 min) and filtered through 0.45
and 0.22 µm syringe filters (Merck Millipore, Burlington, MA, USA). Finally, EVs were concentrated
by double ultracentrifugation in a Beckman L870M ultracentrifuge (100,000× g, 70 min, 4 ◦C) and
resuspended in DPBS [15,16] for further experimental usage as Ts cell EVs. In some cases, EVs were
incubated with anti-miR-150 (miRIDIAN Hairpin Inhibitor of Mouse mmu-miR150, Dharmacon, GE
Healthcare, Lafayette, CO, USA) at 37 ◦C for 1 h, in a dose of 3 µg per eventual recipient mouse,
to block the biological activity of miRNA-150, and then washed to remove excessive anti-miR-150
molecules [15]. Where indicated, cells of spleens and lymph nodes of tolerized mice were subjected to
a positive selection assay, as described above.
2.8. Induction and Separation of B1 Cell-Produced EVs
Mice were injected intradermally on Days 0 and 1 with Cas antigen without adjuvant into 4
separate sites of the abdomen (100 µg per mouse, see above) in order to induce production of B1
cell EVs, coated with specific IgM light chains, but devoid of miRNA-150 [11]. Spleens and lymph
nodes of immunized mice were harvested on Day 3 and single cell suspensions were cultured for
48 h in protein-free MDM (2 × 107 cells per ml, 37 ◦C, 5% CO2). Supernatants from cell cultures
were then centrifuged twice (300× g and 3000× g, for 15 min) and filtered through 0.45 and 0.22 µm
syringe filters. B1 cell-produced EVs were concentrated by ultracentrifugation in a Beckman L870M
ultracentrifuge (100,000× g, 70 min, 4 ◦C) and resuspended in DPBS. In some cases, B1 cell EVs were
incubated overnight on ice with miRNA-150 (miRIDIAN Mimic Mouse mmu-miR-150, Dharmacon,
GE Healthcare, Lafayette, CO, USA), in a dose of 3 µg per eventual mouse recipient, and then washed
to remove excessive miRNA-150 molecules.
2.9. Antigen-Affinity Chromatographic Separation of Cas-Specific EVs
Soluble Cas antigen or purified anti-CD9 monoclonal antibodies (BD Biosciences, San Diego,
CA, USA) were linked to cyanogen bromide-activated Sepharose 4FF (fast flow; Pharmacia, Uppsala,
Sweden) according to the manufacturer’s procedure. Supernatant from tolerized mouse lymph node
and spleen suppressive cell culture was then applied onto either Cas- or anti-CD9- Sepharose-filled
columns. The fraction of nanovesicles that first passed through the column was collected as flow
through (FT, i.e., Cas-non-binding or CD9 negative EVs), and, after column washing with DPBS, the
fraction of nanovesicles that was eluted with 5 M guanidine HCl (pH = 4.7) was collected as eluate (i.e.,
Cas-binding or CD9 positive EVs). Both fractions were filtered through 0.45 and 0.22 µm filters and
ultracentrifuged twice in DPBS (100,000× g, 70 min, 4 ◦C) [11].
2.10. Suppression of Effector Cells Tested in Adoptive Transfer
DTH effector cells collected as above from spleens and lymph nodes of Cas-immunized mice were
incubated with Ts cell EVs for 30 min in 37 ◦C, which was followed by washing in DPBS and 70 µm
nylon mesh filtration. Cell suspensions in DPBS were transferred intravenously to naive, anesthetized
recipients in a ratio of 7 × 107 cells per mice. The next day, animals were ear-challenged by intradermal
administration of 10 µL of Cas and ear thickness was measured after 24 h, as described above.
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Approximately 1.3 × 1010 EVs were used either in adoptive transfer per 7 × 107 effector cells per
mouse or as a single dose administered to actively immunized mouse. The exact quantity of EVs was
estimated using nanoparticle tracking analysis as described in detail previously [11].
2.11. Cytometric Analysis of EVs and Antibody Light Chains
Aldehyde/sulfate latex beads of 4 µm size (Life Technologies, Thermo-Fisher Scientific, Carlsbad,
CA, USA) were incubated in DPBS with Ts cell EVs in a total volume of 1 mL of DPBS for 2 h at room
temperature with gentle agitation. Afterwards, EV-coated beads were blocked with 100 mM glycine for
30 min at room temperature with gentle agitation. After washing and resuspending in DPBS, EV-coated
beads were stained with fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies against
mouse kappa light chains (BD Biosciences, San Diego, CA) and/or phycoerythrin (PE)-conjugated
monoclonal antibodies against mouse CD9, CD63, or CD81 tetraspanins (BD Biosciences, San Diego,
CA, USA) and acquired by a BD FACSCalibur (BD Bioscience, San Jose, CA, USA).
2.12. Test of Different Routes of Therapeutic EV Administration and Active Tolerance Induction
Ts cell-derived EVs or B1 cell-produced EVs were administered to the Cas-immunized animals
intradermally, intraperitoneally, intravenously or per os in equal doses (see above) at the peak
of the allergic response, i.e., 24 h post-challenge. Ear thickness was measured up to 120 h after
challenge by a blinded observer, unaware of the experimental protocol, using an engineer’s micrometer
(Mitutoyo, Kawasaki, Japan). Otherwise, mice, 5 days prior to active immunization, had been injected
intravenously with 10% suspension of syngeneic erythrocytes conjugated with Cas antigen, and
subsequent ear swelling was elicited as above 5 days after immunization.
2.13. MHC Criss-Cross Testing
DTH effector cells collected from Cas-immunized CBA, BALB/c, or C57BL/6 mice were incubated
with Ts cell EVs obtained from CBA mice tolerized to Cas antigen. Next, EV-pulsed or non-pulsed
effector cells were intravenously transferred to naive mice of respective strain. On the following
day, mice were intradermally ear-challenged with Cas antigen, and ear thickness was measured as
described above.
2.14. Statistical Analysis
Readings were done twice on both ears, and the inflammatory response induced in each mouse
was expressed as a mean of the 4 measurements. After meeting of test assumptions, one-way analysis
of variance (ANOVA) with post-hoc RIR Tukey test was used to evaluate the statistical significance
between the groups with p < 0.05 taken as a minimum level of significance, which was marked in the
figures as * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
3. Results
3.1. Soluble Casein Antigen Induces Allergic Reaction
Mice intradermally immunized and challenged with soluble Cas antigen fractions hydrolyzed in
either NaHCO3 or NaOH, developed a significantly greater ear swelling response, when compared to
the negative control group of mice only challenged with respective Cas fraction (Figure 1). In addition,
ear swelling response peaked 24 h after challenge in immunized animals, which resembles DTH
reaction. Thus, we assumed that Cas antigen preserves its immunogenicity during alkaline hydrolysis
and is able to induce DTH reaction in mice after intradermal administration without an adjuvant.
Besides, inflammatory reactions caused by immunization with both fractions of soluble Cas antigen
were comparable, so we decided to mix them in order to use in further experiments.
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Figure 1. Immunogenicity of soluble casein (Cas) antigen obtained by alkaline hydrolysis with 
either NaHCO3 or NaOH. Mice had been intradermally (id) immunized with a saline solution of 
soluble Cas antigen (100 µg per mouse) 5 days before challenging by id administration of the same 
Cas solution (5 µg per earlobe). Twenty-four hours later ear swelling response was measured and 
expressed as mean ± SD [units (U) × 10-2 mm] (n = 4, N = 3). **** p < 0.0001. 
3.2. CD4+ T Cells and Macrophages Mediate the Effector Phase of DTH Reaction to Cas Antigen 
Phenotype of DTH effector cells mediating allergic reaction in Cas-immunized mice was 
assessed using negative and positive selection assays (Figure 2). Statistically significant decrease in 
ear swelling in comparison to a positive control was observed in mice depleted of CD4+ T 
lymphocytes or macrophages prior to adoptive transfer, which indicates that both cell populations 
are important for induction of DTH reaction to Cas antigen. The inflammatory response in mouse 
recipients of macrophage-depleted DTH effector cells was noticeably higher than that in groups 
deprived of CD4+ T cells, which is possibly caused by the activity of a recipient’s macrophages, 
which can still elicit inflammatory response of transferred effector CD4+ T cells. 
Figure 1. Immunogenicity of soluble casein (Cas) antigen obtained by alkaline hydrolysis with either
NaHCO3 or NaOH. Mice had been intradermally (id) immunized with a saline solution of soluble Cas
antigen (100 µg per mouse) 5 days before challenging by id administration of the same Cas solution
(5 µg per earlobe). Twenty-four hours later ear swelling response was measured and expressed as
mean ± SD [units (U) × 10−2 mm] (n = 4, N = 3). **** p < 0.0001.
3.2. CD4+ T Cells and Macrophages Mediate the Effector Phase of DTH Reaction to Cas Antigen
Phenotype of DTH effector cells mediating allergic reaction in Cas-immunized mice was assessed
using negative and positive s lecti n assays (Figure 2). Statistically significant decrease in ear swelling
in comparison to a positive control was observed in mice depleted of CD4+ T lymphocyt s or
mac ophages prior to adoptive ransfer, which i dicates that both cell populations are important
for induction of DTH eaction to Cas antigen. The i flammatory respon e in m use recipients of
m crophage-depleted DTH effector cells was noticeably high r than that in groups d prived of CD4+
T c lls, which is possibly caus d by the activity of a recipient’s macrophages, which can still elicit
inflammatory response of transferred effector CD4+ T cells.
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which 24 h later were challenged by id administration of the same Cas solution (5 µg per earlobe). 
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(n = 5, N = 2), * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
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Tetraspanins and Are Specific to Casein due to Expression of Antibody Light Chains 
Phenotype of suppressive cells was confirmed in positive selection according to CD8 
expression. Selected, CD8+ enriched and CD8 negative cells were cultured separately for 48 h, and 
the pelleted EVs from ultracentrifuged culture supernatant were incubated with DTH effector cells 
prior to adoptive transfer. Statistically significant decrease in ear swelling was observed in 
challenged recipient mice had been administered with DTH effector cells incubated with EVs 
released by either CD8+ T cell enriched or non-selected cells from tolerized mouse lymph nodes 
and spleens (Figure 3A). This observation confirmed that the population of CD8+ T lymphocytes is 
responsible for the production of suppressive, miRNA-150-carrying EVs. By means of flow 
cytometry, Ts cell EVs were shown to express CD9 and CD81 tetraspanins, and CD9+ EVs eluted 
from anti-CD9 chromatography column suppressed DTH effector cells (Figures 3B and 3C). 
Figure 2. Phenotyping of effector cells of delayed-type hypersensitivity (DTH) to soluble casein (Cas)
antigen. Mice had been intradermally (id) immunized with a saline solution of soluble Cas antigen
(100 µg per mouse) 5 days before harvest of lymph nodes and spleens containing effector cells, which
were then subjected to positive (A) or negative (B) selection assays by, respectively, magnetic-advanced
cell sorting or depletion with either monoclonal antibodies and complement or nylon wool separation.
Afterwards, selected effector cells were transferred to naive recipients, which 24 h later were challenged
by id administration of the same Cas solution (5 µg per earlobe). After 24 h, ear swelling response was
measured and expressed as delta ± SEM [units (U) × 10−2 mm] (n = 5, N = 2), * p < 0.05; ** p < 0.01;
*** p < 0.001; **** p < 0.0001.
3.3. CD8+ T Cells Are Responsible for Production of Suppressive EVs that Express CD9 and CD81
Tetraspanins and Are Specific to Casein due to Expression of Antibody Light Chains
Phenotype of suppressive cells was confirmed in positive selection according to CD8 expression.
Selected, CD8+ enriched and CD8 negative cells were cultured separately for 48 h, and the pelleted EVs
from ultracentrifuged culture supernatant were incubated with DTH effector cells prior to adoptive
transfer. Statistically significant decrease in ear swelling was observed in challenged recipient mice had
been administered with DTH effector cells incubated with EVs released by either CD8+ T cell enriched
or non-selected cells from tolerized mouse lymph nodes and spleens (Figure 3A). This observation
confirmed that the population of CD8+ T lymphocytes is responsible for the production of suppressive,
miRNA-150-carrying EVs. By means of flow cytometry, Ts cell EVs were shown to express CD9 and
CD81 tetraspanins, and CD9+ EVs eluted from anti-CD9 chromatography column suppressed DTH
effector cells (Figure 3B,C). Interestingly, the flow through fraction of the anti-CD9 column increase
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DTH ear swelling. We assumed that this may result from the presence of Cas-specific antibody light
chains non-associated with CD9+ EVs in the flow through fraction from the anti-CD9 column, as
detected by flow cytometry (Figure 3B). Furthermore, Ts cell EVs expressed antibody light chains
(Figure 3B), which could be responsible for their antigen specificity. To test this assumption, suppressive
EVs were separated by antigen-affinity chromatography. Cas-binding EVs eluted from the Cas column,
when incubated with DTH effector cells prior to adoptive transfer, significantly suppressed the elicited
DTH ear swelling (Figure 3D). These results prove that suppressive EVs are Cas-specific.
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Figure 3. Suppression of delayed-type hypersensitivity (DTH) to soluble casein (Cas) antigen is
mediated by CD8+ suppressor T (Ts) cell-derived extracellular vesicles (EVs) expressing CD9 and CD81
tetraspanins and Cas-specific antibody light chains. (A) Mice had been intravenously administere
with Cas-coupled syngeneic red blood cells, followed by intradermal (id) immunization with a saline
solution of soluble Cas antigen (100 µg per mouse) 3 days before harvest of lymph nodes and spleens
containing Ts cells, which were then subjected to positive selection assay, i.e., agnetic-advanced cell
sorting, and cultured for subsequent 48 h. The resulting supernatant was filtered and ultracentrifuged
to concentrate Ts cell EVs, used to treat DTH effector cells prior to adoptive transfer to recipients,
challenged 24 h later by id administration of the same Cas solution (5 µg per earlobe). After 24 h, ear
swelling response was measured and expressed as delta ± SEM [units (U) × 10−2 mm] (n = 5, N = 2). (B)
Ts cell EVs were coated onto latex beads, stained with monoclonal antibodies against CD9, CD63, and
CD81 tetraspanins or against mouse antibody kappa light chains, and then analyzed by flow cytometry
(n = 3, N = 2). (C) Ts cell EVs were separated by antigen affinity chromatography on column filled with
Sepharose coated with anti-CD9 monoclonal antibodies, and the resulting fractions, i.e., flow through
or eluate, were used to treat DTH effector cells prior to adoptive transfer to recipients, challenged 24 h
later by id administration of the same Cas solution (5 µg per earlobe). After 24 h, ear swelling response
was measured and expressed as delta ± SEM [units (U) × 10−2 mm] (n = 5, N = 2). (D) Ts cell EVs were
separated by antigen affinity chromatography on column filled with Cas-coated Sepharose, and the
resulting fractions, i.e., flow through or eluate, were used to treat DTH effector cells prior to adoptive
transfer to recipients, challenged 24 h later by id administration of the same Cas solution (5 µg per
earlobe). After 24 h, ear swelling response was measured and expressed as delta ± SEM [units (U) ×
10−2 mm] (n = 5, N = 3). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
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3.4. Cas-Coupled Erythrocyte Intravenous Administration Induces Tolerance and the Resulting EVs Are
Suppressive after Administration via Different Routes
Mice were tolerized with syngeneic erythrocytes conjugated with Cas antigen (Cas-MRBC), prior
to intradermal immunization with Cas. Figure 4A shows the average inflammatory response after 24,
48, 72, 96, and 120 h after challenge with Cas antigen. Statistically significant decrease in ear swelling
in the case of tolerized mice was then observed at every time point, which proves that intravenous
tolerization with Cas-MRBC prevents the development of DTH to Cas, likely due to Ts cell EVs
carrying miRNA-150.
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Figure 4. Suppression of delayed-type hypersensitivity (DTH) to soluble casein (Cas) antigen is induced
by intravenous (iv) injection of Cas-coupled syngeneic red blood cells and by CD8+ suppressor T
(Ts) cell-derived extracellular vesicles (EVs) administered via different routes. (A) Mice had been
administered iv with Cas-coupled syngeneic red blood cells, which was followed by intradermal (id)
immunization with a saline solution of soluble Cas antigen (100 µg per mouse) 5 days before challenging
by id ad inistration of the same Cas solution (5 µg per earlobe). Subsequent ear swelling response
w s measu d d ily up to 120 h after challenge and expr s ed as delta ± SEM [units (U) × 10−2 mm]
(n = 5, N = 2). (B) Mice had bee id immunized with a saline solution of soluble Cas antigen (100 µg
per mouse) 5 days before challenging by id administration of the same Cas solution (5 µg per earlobe).
After measurement of 24 h ear swelling, Ts cell EVs were administered intraperitoneally (ip), id, iv,
or per os, and subsequent ear swelling response was measured daily up to 120 h after challenge and
expressed as delta ± SEM [units (U) × 10−2 mm] (n = 5, N = 2). * p < 0.05; ** p < 0.01; *** p < 0.001;
**** p < 0.0001.
Thus, Ts cell EVs were administered to Cas-immunized mice intravenously (iv), intradermally
(id), intraperitoneally (ip), or per os, at the peak of 24 h inflammatory response. Figure 4B presents
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the average inflammatory response in each group, measured daily up to 120 h after challenge with
Cas antigen. All administration routes induced a significant decrease in ear swelling in comparison to
the positive control, with the most notable decrease observed when Ts cell EVs were administered
intradermally, which is the route used for immunization of animals, and per os, which is the natural
means of immunization with food protein allergens, such as Cas.
3.5. Ts Cell EVs Obtained from Tolerized CBA Mice Suppress the Adoptively Transferred DTH Reaction in
Different Strains of Mice
DTH effector cells of CBA, BALB/c, or C57BL/6 mice immunized with Cas antigen were incubated
with Ts cell EVs from CBA mice tolerized to Cas. Next, the effector cells were administered iv to the
naive recipients of respective strain. A significant decrease in ear swelling was observed in all tested
strains in groups treated with CBA Ts cell EVs, with the strongest effect detected in the case of CBA
mice (Figure 5A), which suggests that EV action is rather not MHC-restricted.
3.6. The Blockade of miRNA-150 Activity in EVs Deprives Them of Suppressive Properties
To confirm, whether miRNA-150 is indeed the suppressive component of Ts cell EVs, they were
incubated with antagonist of miRNA-150 (anti-miR-150) for 1 h before incubation with DTH effector
cells from animals immunized with Cas antigen. Then, DTH effector cells were administered iv to
naive mice that were ear-challenged with Cas antigen on the following day. Significant suppression of
inflammatory response was observed in a group administered with DTH effector cells incubated with
intact Ts cell EVs, while no significant suppression was observed in a group treated with inactivated
miRNA-150 (Figure 5B). This confirms that miRNA-150 provides suppressive capacity of Ts cell EVs.
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Figure 5. Major histocompatibility complex (MHC) restriction and dependence on miRNA-150 of
suppression of delayed-type hypersensitivity (DTH) to soluble casein (Cas) antigen. (A) Mice of CBA,
BALB/c, or C57BL/6 strains had been intradermally (id) immunized with a saline solution of soluble Cas
antigen (100 µg per mouse) 5 days before harvest of lymph nodes and spleens containing effector cells,
which were then treated with Cas-specific suppressor T (Ts) cell-derived extracellular vesicles (EVs) of
t lerized CBA mice. After ards, effector cells were transferred to naive recipients of respective strain,
which 24 h later were challenged by id a ministration of the same Cas solution (5 µg per earlob ). After
24 h, ear sw lling response was measured and expressed as delt ± SEM [units (U) × 10−2 mm] (n = 4,
N = 2). (B) Part of Ts cell EVs was incubated with miRNA-150 antagonist, i.e., nti-miR-150, ior to
treatment of DTH effector cells, which were then adoptively transferred to recipient , challenged 24
later by id administration of the same Cas solution (5 µg p r earlobe). A t r 24 h, ear s elling response
was measured and expressed as delta ± SEM [units (U) × 10−2 mm] (n = 5, N = 3). **** p < 0.0001.
3.7. Cas-Specific B1 Cell-Produced EVs Gain Suppressive Activity after Incubation with miRNA-150 and
Express Therapeutic Potential after Administration via Different Routes
B1 cell-derived EVs wer proposed effective hi les for ransmiss of regulatory miRNAs.
To v rify this hypothesis, we had incubated B1 cell-derived EVs from Cas-immunized mice with
miRNA-150 and used them to treat Cas-specific DTH effector cells, which were next administered
to naive recipients. No significant suppression of inflammatory response was observed in a group
administered with B1 cell-produced EVs alone, while B1 cell EVs supplemented with miRNA-150
significantly suppressed DTH reaction (Figure 6A). On the other hand, ovalbumin-specific B1 cell
EVs supplemented with miRNA-150 failed to suppress Cas-specific DTH effector cells (Figure 6A).
These results prove that B1 cell EVs themselves are non-suppressive but can gain suppressive
properties when supplemented with miRNA-150 and that they suppress DTH reaction afterwards in
an antigen-specific manner.
To verify Cas-specific, B1 cell EVs’ therapeutic potential after supplementation with miRNA-150,
they were administered to mice intravenously (iv), intradermally (id), intraperitoneally (ip), or per os
at the peak of 24 h inflammatory response to Cas antigen. The most notable decrease in ear swelling
response was observed in a group of mice administered with EVs per os (Figure 6B), analogously to Ts
cell EVs (see Figure 4B). Statistically significant suppression was also noted in groups administered
with EVs ip and id, while there were no significant differences between the positive control and the
iv treated group until 120 h (Figure 6B). These results confirm that Cas-specific B1 cell EVs can gain
suppressive properties when supplied with miRNA-150 and that the most effective method of their
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administration is the same as the natural route of immunization with Cas antigen, i.e., the oral route,
which is well tolerated by patients.
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Figure 6. Suppression of delayed-type hypersensitivity (DTH) to soluble casein (Cas) antigen by
miRNA-150-s lemented B1 cell-derived extracellular vesicles (EVs) of Cas-immunized mice. (A) Mice
had been intradermally (id) immunized with a saline solution of soluble Cas antigen or ovalbumin
(OVA, both 100 µg per mouse) 3 days before harvest of lymph nodes and spleens containing B1 cells,
which were cultured for a subsequent 48 h. The resulting supernatant was filtered and ultracentrifuged
to concentrate Cas-specific or OVA-specific B1 cell EVs, then supplemented with miRNA-150 prior to
treatment of Cas-specific DTH effector cells, which were adoptively transferred to recipients, challenged
24 h later by id administration of the same Cas solution (5 µg per earlobe). After 24 h, ear swelling
response was measured and expressed as delta ± SEM [units (U) × 10−2 mm] (n = 5, N = 2). (B) Mice
had been id immunized with a saline solution of soluble Cas antigen (100 µg per mouse) 5 days before
challenging by id administration of the same Cas solution (5 µg per earlobe). After measurement of 24 h
ear swelling, miRNA-150-supplemented, Cas-specific B1 cell EVs were administered intraperitoneally
(ip), id, intravenously (iv), or per os, and subsequent ear swelling response was measured daily up to
120 h after challenge and expressed as delta ± SEM [units (U) × 10−2 mm] (n = 4, N = 2). * p < 0.05;
** p < 0.01; *** p < 0.001; **** p < 0.0001.
4. Discussion
Food allergy is considered a consequence of a breakdown of oral tolerance. This process can be
initiated by disturbances in antigen uptake caused by increased skin and gut permeability that lead to
dissemination of the food allergen, presentation of its epitope by antigen-presenting cells (APCs), and
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sensitization [17]. Animals in the experiments were fed with casein-free chow in order to prevent any
previous contact with the allergen and to exclude the possibility of oral tolerance development. A new
mouse model of DTH to Cas was established using soluble Cas antigen administered intradermally
without an adjuvant, and the inflammatory response, peaking at 24 h after challenge, was also effectively
transferred from immunized donors to naive recipients, as unraveled by CD4+ T lymphocytes and
macrophages as effector cells. The important role of macrophages in inflammatory reactions suggests
that CD4+ T lymphocytes belong to the Th1 subpopulation. According to Lerch's and Pichler’s
subclassification of cell-mediated hypersensitivity, DTH to Cas can be classified as a IVa allergic
reaction [6].
EVs and their ability to transport bioactive molecules, such as miRNAs, to acceptor cells are a
new, promising tool that may be used in diagnosis and therapy for a variety of human diseases [18,19].
Bai et al. reported that miRNA-150 may inhibit the proliferation and promote the cell cycle arrest
in thyroid cancer cells [20]. Exogenous miRNA-150 was also described to inhibit proliferation and
metastasis and to enhance cell apoptosis in human osteoblasts [21]. Chen et al. investigated the
therapeutic effect of mesenchymal stem cell-derived EVs carrying miRNA-150-5p in potential therapy
of rheumatoid arthritis. Injection of miRNA-150-loaded EVs reduced joint destruction by inhibition of
hyperplasia and angiogenesis in a mouse model of collagen-induced arthritis [22]. miRNA-150 was
proved to be a regulatory factor carried by Ts cell-derived exosomes [11]. Suppressive capacity of Ts
cell EVs was confirmed by numerous independent groups in a mouse model of contact sensitivity
to haptens [13]. We managed to separate Ts cell EVs from cell culture supernatant from animals
tolerized to food protein, such as Cas, and to prove its ability to suppress inflammatory reaction in
DTH to Cas antigen both in adoptive transfer and in active immunization. Cas-specific Ts cell EVs
treated with miRNA-150 antagonist prior to incubation with Cas DTH effector cells proved to be
inactive. Additionally, B1 cell-derived EVs did not suppress DTH reaction to Cas antigen, unless they
were supplemented with miRNA-150. These results confirmed that Ts cell EVs, produced by animals
tolerized to Cas antigen, owe their suppressive activity to miRNA-150 that is carried by EVs derived
from CD8+ Ts cells and not B1 cells.
We confirmed that suppressive EVs in DTH to Cas, like in CS to haptens, were a product of CD8+ Ts
lymphocytes by means of positive selection. Furthermore, antigen-specificity of Ts cell EVs was tested
in antigen-affinity chromatography and the eluate from the column proved to be strongly suppressive
in contrast to flow through. Bryniarski et al. tested antigen-specificity of EVs in CS to haptens in
both antigen-affinity chromatography and in a crisscross experiment, where trinitrophenol-specific
Ts cell EVs failed to suppress inflammatory reaction to oxazolone. The antigen-specificity of EVs
was then demonstrated by means of flow cytometry to be the result of IgM antibody light chain
(LC) coating [11]. Those LCs are produced by B1 lymphocytes activated by immunization with an
antigen, which follows the tolerization with antigen-coupled syngeneic red blood cells [15]. Current
results demonstrated the presence of LC on Cas-specific Ts cell EVs, which additionally confirms
their antigen-specificity. Furthermore, miRNA-150-supplemented B1 cell-derived EVs from mice
immunized with ovalbumin failed to suppress Cas-induced DTH, which brought more evidence for
the LC-mediated specificity of EV action. IgM antibodies produced by B1 lymphocytes are usually
characterized by low specificity to antigen as their secretion does not require signals from helper
T cells. Lately, it was presented that a special subset of B1a cells generates high antigen-affinity
IgM antibodies and free LCs as a consequence of immunoglobulin V-region mutations induced by
activation-induced cytidine deaminase. B1a lymphocytes are suggested to initiate early responses in
immune resistance to pneumococcal pneumonia, CS, and DTH [23,24], which was herein indirectly
confirmed by the enhancement of DTH reaction caused by the flow through fraction of the anti-CD9
column, demonstrated to contain Cas-binding LC. Recent findings confirm that B1 cell-derived LCs
provide the specificity of EVs in CS to haptens and enable execution of their suppressive function, as the
Ts cell EVs of B-cell-deficient or immunoglobulin-deficient mice are non-suppressive [25]. Previously,
it was demonstrated that injection of haptenized MRBC before contact sensitization with oxazolone
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and elicitation of CS ear swelling response leads to suppression of inflammatory response in wild-type
mice [25]. Here, we confirmed that double injection of cas-MRBC prior to immunization with the
Cas antigen protected animals from developing of DTH reaction to Cas. The results suggest that
animals tolerized with Cas antigen actively produce Ts cell EVs that prevent elicitation of inflammatory
response up to 120 h.
Ts cell EVs modulate inflammatory response indirectly. Transfer of effector cells incubated
with peritoneal macrophages treated previously with Ts cell EVs inhibited reaction in CS effector
cell recipients [26]. Lately, it was confirmed that EVs containing miRNA-150 act as mediators in
communication between effector T cells and APC, since mice depleted of macrophages cannot be
effectively tolerized [27]. APCs express major histocompatibility complex class II (MHC II) on their
surface that was reported to be also expressed on their EVs, which enables targeting of CD4+ T cells [28].
Here, we investigated whether the suppressive effect of Ts cell EVs depends on MHC II by treatment of
DTH effector cells from CBA, BALB/c, and C57BL/6 mice immunized with Cas with EVs collected from
CBA mice tolerized to Cas antigen. In our experiment, CBA Cas-specific Ts cell EVs were effective
in each strain. This suggests that T cell-derived EVs, in contrast to T cells themselves, cannot check
MHC homology, which implies that those EVs, like miRNAs, may mediate a highly conserved mode
of communication across strains.
We tested four different routes of Ts cell EV administration and all of them effectively suppressed
inflammatory response in active immunization. Interestingly, the most effective routes of EV
administration, i.e., id and per os, were also the routes of immunization with the antigen. In our
experiments, animals were immunized intradermally and the natural route of immunization with food
protein allergens would be through the gastrointestinal tract. Furthermore, the oral route is also the
natural means of food tolerance induction. Intestinal epithelial cell-derived EVs, carrying αvβ6 integrin
and food antigens, were reported to stimulate tolerance in dendritic cells (DCs) and promote regulatory
T cell development in a model of oral tolerance induction [29]. Previously, DCs were described to
directly sample the content of intestine lumen through the trans-epithelial dendrites [17,30]. Food
antigens could also be internalized in Peyer’s patches and captured by APCs, which then migrate to
lymph nodes and activate effector or regulatory T cells [31]. These mechanisms of oral tolerance create
a suitable opportunity for Ts cell EVs to reach APCs and transfer the suppressive information. In a
following experiment, we tested the same routes of administration of miRNA-150-supplemented B1
cell EVs, and the oral administration again happened to be the most effective. Statistically significant
differences were also observed when EVs were administered ip and id, which is possibly a result
of particularly easy access to resident macrophages and DCs in peritoneal cavity and skin [32,33].
Intravenous injection of the miRNA-150-supplemented B1 cell EVs to Cas-immunized mice was not
effective until 120 h in contrast to previous experiments with Ts cell EVs, where all routes suppressed
inflammatory reaction within 24 h of administration. Our results may indicate that miRNA-150 is not
internalized by B1 cell EVs but adheres to their surface instead, where it is susceptible to enzymatic
hydrolysis. In contrast, when miRNA-150 is originally sorted to EVs in MVB of Ts cells, it is protected
from ribonucleases activity in serum. Thus, miRNA-150-supplemented B1 cell EVs require more time
to access sufficient amount of APCs to deliver the suppressive information.
It is worth noting that EVs are resistant to harsh conditions, including very low pH and activity of
digestive enzymes, which enables the protection of contained RNA cargo, as reported in the case of
the transmission of dietary miRNAs associated with EVs via intestines [34,35]. This was true also for
maternal milk exosome RNA cargo transferring epigenetic information to neonates after intestinal
absorption [36], likely via epithelial cell endocytosis [37,38]. Interestingly, EV-associated miRNAs
absorbed via intestinal barrier have been proposed to regulate immunity [39], and our current results
seem to confirm this assumption.
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5. Conclusions
We standardized a method to produce immunogenic, soluble Cas antigen activating DTH when
administered intradermally without an adjuvant. Further, we developed a new model of DTH to a
milk protein allergen and identified the phenotype of effector cells responsible for the inflammatory
reaction as CD4+ Th1 lymphocytes and macrophages. The possibility of antigen-specific suppression of
cell-mediated reaction in allergic response to food protein, such as Cas, was also confirmed. Suppressive
EVs obtained from cell supernatants of mice tolerized to Cas were a product of CD8+ Ts lymphocytes.
miRNA-150 was described as the suppressive compound of Cas-specific Ts cell EVs. Animals tolerized
to Cas prior to immunization actively produced Ts cell EVs that protected them from developing DTH
response to Cas. The oral route of administration was the most effective for treatment with either Ts
cell EVs or miRNA-150-supplemented B1 EVs, as it is the natural route of oral tolerance development.
Cas-specific Ts cell EVs derived from CBA mice suppressed inflammatory reactions in different strains
of mice immunized to Cas antigen, which suggests that the intercellular communication via suppressive
EVs is conserved among strains.
Author Contributions: Conceptualization: M.W., K.N., P.W.A., and K.B.; funding acquisition: P.W.A. and K.B.;
investigation: M.W., K.N., B.N., and K.B.; methodology: B.N. and P.W.A.; supervision: K.B.; validation: M.W.,
K.N., and K.B.; visualization: M.W. and K.N.; writing—original draft: M.W.; writing—review & editing: K.N.
and K.B.
Funding: This research was supported by the grant of Polish Ministry of Science and Higher Education No
K/ZDS/006148 to K.B. and partly by grant No AI-1053786 from the National Institutes of Health to P.W.A.
Conflicts of Interest: The authors declare no conflict of interest.
References
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7. Wróblewska, B.; Jędrychowski, L. Effect of technological modification on the immunoreactive properties of
cow milk proteins. Alergia Astma Immunol. 2003, 8, 157–164. (In Polish)
8. Hochwallner, H.; Schulmeister, U.; Swoboda, I.; Spitzauer, S.; Valenta, R. Cow’s milk allergy: From allergens
to new forms of diagnosis, therapy and prevention. Methods 2014, 66, 22–33. [CrossRef]
9. Jêvinen, K.-M.; Laine, S.T.; Jêvenpêê, A.-L.; Suomalainen, H.K. Does Low IgA in Human Milk Predispose the
Infant to Development of Cow’s Milk Allergy? Pediatr. Res. 2000, 48, 457–462.
10. Järvinen, K.M.; Westfall, J.E.; Seppo, M.S.; James, A.K.; Tsuang, A.J.; Feustel, P.J.; Sampson, H.A.; Berin, C.
Role of maternal elimination diets and human milk IgA in the development of cow’s milk allergy in the
infants. Clin. Exp. Allergy 2014, 44, 69–78. [CrossRef] [PubMed]
11. Bryniarski, K.; Ptak, W.; Jayakumar, A.; Püllmann, K.; Caplan, M.J.; Chairoungdua, A.; Lu, J.; Adams, B.D.;
Sikora, E.; Nazimek, K.; et al. Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor
T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. J. Allergy Clin. Immunol. 2013, 132,
170–181. [CrossRef]
Nutrients 2019, 11, 907 17 of 18
12. Nazimek, K.; Bryniarski, K.; Santocki, M.; Ptak, W. Exosomes as mediators of intercellular communication:
clinical implications. Pol. Arch. Intern. Med. 2015, 125, 370–380. [CrossRef]
13. Ptak, W.; Nazimek, K.; Askenase, P.W.; Bryniarski, K. From Mysterious Supernatant Entity to miRNA-150 in
Antigen-Specific Exosomes: A History of Hapten-Specific T Suppressor Factor. Arch. Immunol. Ther. Exp.
2015, 63, 345–356. [CrossRef] [PubMed]
14. Szczepanik, M.; Akahira-Azuma, M.; Bryniarski, K.; Tsuji, R.F.; Kawikova, I.; Ptak, W.; Kiener, C.;
Campos, R.A.; Askenase, P.W. B-1 B Cells Mediate Required Early T Cell Recruitment to Elicit Protein-Induced
Delayed-Type Hypersensitivity. J. Immunol. 2003, 171, 6225–6235. [CrossRef]
15. Bryniarski, K.; Ptak, W.; Martin, E.; Nazimek, K.; Szczepanik, M.; Sanak, M.; Askenase, P.W. Free Extracellular
miRNA Functionally Targets Cells by Transfecting Exosomes from Their Companion Cells. PLoS ONE 2015,
10, e0122991. [CrossRef] [PubMed]
16. Stremersch, S.; Brans, T.; Braeckmans, K.; De Smedt, S.; Raemdonck, K. Nucleic acid loading and fluorescent
labeling of isolated extracellular vesicles requires adequate purification. Int. J. Pharm. 2018, 548, 783–792.
[CrossRef]
17. Wambre, E.; Jeong, D. Oral Tolerance Development and Maintenance. Immunol Allergy Clin. North Am. 2018,
38, 27–37. [CrossRef]
18. Hu, G.; Drescher, K.M.; Chen, X.-M.; Chen, X. Exosomal miRNAs: Biological Properties and Therapeutic
Potential. Front. Genet. 2012, 3, 56. [CrossRef] [PubMed]
19. Rashed, M.H.; Bayraktar, E.; Helal, G.K.; Abd-Ellah, M.F.; Amero, P.; Chavez-Reyes, A.; Rodriguez-Aguayo, C.;
Pichler, M. Exosomes: From Garbage Bins to Promising Therapeutic Targets. Int. J. Mol. Sci. 2017, 18, 538.
[CrossRef]
20. Bai, D.; Sun, H.; Wang, X.; Lou, H.; Zhang, J.; Wang, X.; Jiang, L. MiR-150 Inhibits Cell Growth In Vitro and In
Vivo by Restraining the RAB11A/WNT/β-Catenin Pathway in Thyroid Cancer. Med Sci. 2017, 23, 4885–4894.
[CrossRef]
21. Li, X.; Chen, L.; Wang, W.; Meng, F.-B.; Zhao, R.-T.; Chen, Y. MicroRNA-150 Inhibits Cell Invasion and
Migration and Is Downregulated in Human Osteosarcoma. Cytogenet. Genome Res. 2015, 146, 124–135.
[CrossRef] [PubMed]
22. Chen, Z.; Wang, H.; Xia, Y.; Yan, F.; Lu, Y. Therapeutic Potential of Mesenchymal Cell–Derived
miRNA-150-5p–Expressing Exosomes in Rheumatoid Arthritis Mediated by the Modulation of MMP14 and
VEGF. J. Immunol. 2018, 201, 2472–2482. [CrossRef] [PubMed]
23. Askenase, P.W.; Bryniarski, K.; Paliwal, V.; Redegeld, F.; Kormelink, T.G.; Kerfoot, S.; Hutchinson, A.T.; Van
Loveren, H.; Campos, R.; Itakura, A.; et al. A subset of AID-dependent B-1a cells initiates hypersensitivity
and pneumococcal pneumonia resistance. Ann. N. Y. Acad. Sci. 2015, 1362, 200–214. [CrossRef] [PubMed]
24. Yamamoto, N.; Kerfoot, S.M.; Hutchinson, A.T.; Dela Cruz, C.S.; Nakazawa, N.; Szczepanik, M.;
Majewska-Szczepanik, M.; Nazimek, K.; Ohana, N.; Bryniarski, K.; et al. Expression of activation-induced
cytidine deaminase enhances the clearance of pneumococcal pneumonia: Evidence of a subpopulation of
protective anti-pneumococcal B1a cells. Immunology 2016, 147, 97–113. [CrossRef]
25. Nazimek, K.; Askenase, P.W.; Bryniarski, K. Antibody Light Chains Dictate the Specificity of Contact
Hypersensitivity Effector Cell Suppression Mediated by Exosomes. Int. J. Mol. Sci. 2018, 19, 2656. [CrossRef]
[PubMed]
26. Zembala, M.; Asherson, G.L. T cell suppression of contact sensitivity in the mouse. II. The role of soluble
suppressor factor and its interaction with macrophages. Eur. J. Immunol. 1974, 4, 799–804. [CrossRef]
27. Nazimek, K.; Ptak, W.; Nowak, B.; Askenase, P.W.; Bryniarski, K. Macrophages play an essential role in
antigen-specific immune suppression mediated by T CD8+ cell-derived exosomes. Immunology 2015, 146,
23–32. [CrossRef]
28. Raposo, G. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996, 183, 1161–1172. [CrossRef]
29. Chen, X.; Song, C.-H.; Feng, B.-S.; Li, T.-L.; Zheng, P.-Y.; Xing, Z.; Yang, P.-C. Intestinal epithelial cell-derived
integrin αβ6 plays an important role in the induction of regulatory T cells and inhibits an antigen-specific
Th2 response. J. Leukoc. Boil. 2011, 90, 751–759. [CrossRef]
30. Wawrzyniak, M.; O’Mahony, L.; Akdis, M. Role of Regulatory Cells in Oral Tolerance. Allergy Asthma
Immunol. Res. 2017, 9, 107–115. [CrossRef]
31. Coombes, J.L.; Powrie, F. Dendritic cells in intestinal immune regulation. Nat. Rev. Immunol. 2008, 8, 435–446.
[CrossRef]
Nutrients 2019, 11, 907 18 of 18
32. Davies, L.C.; Jenkins, S.J.; Allen, J.E.; Taylor, P.R. Tissue-resident macrophages. Nat. Immunol. 2013, 14,
986–995. [CrossRef] [PubMed]
33. Romani, N.; Flacher, V.; Tripp, C.H.; Sparber, F.; Ebner, S.; Stoitzner, P. Targeting skin dendritic cells to
improve intradermal vaccination. Curr. Top. Microbiol. Immunol. 2012, 351, 113–138. [CrossRef] [PubMed]
34. Benmoussa, A.; Lee, C.H.C.; Laffont, B.; Savard, P.; Laugier, J.; Boilard, E.; Gilbert, C.; Fliss, I.; Provost, P.
Commercial Dairy Cow Milk microRNAs Resist Digestion under Simulated Gastrointestinal Tract Conditions.
J. Nutr. 2016, 146, 2206–2215. [CrossRef] [PubMed]
35. Izumi, H.; Kosaka, N.; Shimizu, T.; Sekine, K.; Ochiya, T.; Takase, M. Bovine milk contains microRNA and
messenger RNA that are stable under degradative conditions. J. Dairy Sci. 2012, 95, 4831–4841. [CrossRef]
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